US10385376B2ActiveUtilityPatentIndex 67
21-hydroxylation of steroids
Est. expiryOct 30, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:LATTEMANN CLAUSSTILLGER THOMASJANOCHA BERNDRASSER HANS-FALKRISSOM SEBASTIANANDERKO SIMONEBERNHARDT RITAHANNEMANN FRANK
C12P 33/06C12Y 118/01006C12Y 118/01002C12Y 114/9901C12Y 114/14C12N 15/52C12N 9/0095C12N 9/0087C12N 9/0042C07K 14/245C12P 33/00
67
PatentIndex Score
1
Cited by
26
References
14
Claims
Abstract
Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A process for the hydroxylation of the carbon atom 21 of a steroid, comprising the steps of:
(a) providing a cell expressing:
(i) a heterologous CYP21A2 protein or a functional variant thereof;
(ii) at least one heterologous electron transfer system capable of transferring electrons to CYP21A2; and
(iii) one or more chaperones facilitating folding of CYP21A2; and
(b) adding the steroid to the cell,
wherein the steroid is medrane or deltamedrane.
2. The process of claim 1 , further comprising a step (c) of extracting the 21-hydroxylated steroid from the supernatant of the cell.
3. The process of claim 1 , further comprising adding one or more cell permeabilizing agents to the cell after step (b).
4. The process of claim 1 , wherein the cell is a resting cell.
5. The process of claim 1 , wherein the cell is a prokaryotic cell or a eukaryotic cell.
6. The process of claim 1 , wherein the at least one heterologous electron transfer system comprises:
(a) a CYP21A2 reductase, and/or
(b) a ferredoxin reductase.
7. The process of claim 1 , wherein the one or more chaperones are recombinantly expressed chaperones.
8. The process of claim 1 , wherein the expression of at least one tryptophanase gene is reduced or abolished in the cell.
9. The process of claim 1 , wherein the cell further expresses a heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway.
10. The process of claim 1 , wherein the genes encoding for (i), (ii), and optionally (iii) are comprised in one or more expression cassettes which are integrated into the cell genome.
11. The process of claim 5 , wherein the cell is an E. coli cell.
12. The process of claim 5 , wherein the cell is a yeast cell.
13. The process of claim 9 , wherein the heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway is a hemA gene.
14. The process of claim 6 , wherein the at least one heterologous electron transfer system comprises an NADPH-dependent ferredoxin reductase and a ferredoxin.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.